AFFILIATIONS
1 Boston Medical Center – Brighton, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
ABSTRACT
Background:
Daratumumab-based regimens are now standard of care in newly diagnosed multiple myeloma (NDMM). However, older and frail patients remain underrepresented in pivotal trials, and comparative real-world data evaluating Dara-RVd, Dara-Rd, and RVd are limited.
Methods:
Older adults aged ≥70 years with NDMM diagnosed in 2020 or later who initiated first-line therapy with Dara-RVd, Dara-Rd, or RVd and did not undergo autologous stem cell transplantation were identified using the TriNetX Research Network. For each comparison (Dara-RVd vs RVd, Dara-RVd vs Dara-Rd, Dara-Rd vs RVd), patients were matched using 1:1 propensity score matching including age, sex, race, comorbidities (diabetes, hypertension, chronic kidney disease, ischemic heart disease, heart failure, COPD), extramedullary plasmacytoma, and baseline laboratory values (LDH, albumin, β2-microglobulin, hemoglobin, creatinine, calcium). A frail subgroup was defined by the presence of ≥1 frailty marker (prior fall, BMI ≤18.5 kg/m², malnutrition, sarcopenia, or dependence on enabling devices) within 1 year before diagnosis. Time to next treatment or death (TTNT/death), overall survival (OS), and 1-year emergency department (ED) visits, ICU admissions, and infections (sepsis, bacterial infections) were evaluated. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models.
Results:
A total of 592 Dara-RVd, 560 Dara-Rd, and 803 RVd patients were identified before matching.
In the matched comparison of Dara-RVd and RVd (515 per group; median follow-up 12 vs 27 months), Dara-RVd showed longer TTNT/death (median 63 vs 44 months; HR 0.69, 95% CI 0.54–0.88, p=0.002; 1-year TTNT/death event risk 15% vs 23%) and improved OS (median not reached in either group; HR 0.60, 95% CI 0.44–0.82, p=0.001). Within 1 year, Dara-RVd had fewer ED visits (31% vs 38%, p=0.016) and and similar ICU admission and sepsis rates but fewer bacterial infection rates (25% vs 32%, p=0.007). In the frail subgroup (180 per group after matching), Dara-RVd continued to demonstrate superior TTNT/death (median 41 vs 23 months; HR 0.72, 95% CI 0.53–1.00, p=0.045) and OS (median 63 vs 41 months; HR 0.65, 95% CI 0.44–0.96, p=0.030).
In the matched comparison of Dara-Rd and RVd (484 per group; median follow-up 18 vs 26 months), Dara-Rd showed longer TTNT/death (median 60 vs 43 months; HR 0.67, 95% CI 0.54–0.84, p<0.001; 1-year TTNT/death event risk 17% vs 26%) and improved OS (median not reached vs 71 months; HR 0.68, 95% CI 0.52–0.89, p=0.004). Within 1 year, Dara-Rd had fewer ED visits (31% vs 40%, p=0.003) and similar ICU admission, sepsis, and bacterial infection rates. In the frail subgroup (196 per group after matching), Dara-Rd continued to demonstrate superior TTNT/death (median 37 vs 23 months; HR 0.74, 95% CI 0.55–0.98, p=0.036) but not OS (median 60 vs 48 months; HR 0.78, 95% CI 0.56–1.10, p=0.15).
In the matched comparison of Dara-RVd and Dara-Rd (368 per group; median follow-up 12 vs 19 months), outcomes were comparable for TTNT/death (median 61 vs 60 months; HR 1.10, 95% CI 0.81–1.48, p=0.54; 1-year TTNT/death event risk 15% vs 16%) and OS (HR 1.10, 95% CI 0.74–1.63, p=0.64), with similar ED visits, ICU admission, sepsis, and bacterial infection rates. In the frail subgroup (119 per group after matching), Dara-RVd and Dara-Rd remained comparable for TTNT/death (median 35 vs 37 months; HR 1.06, 95% CI 0.69–1.63, p=0.78) and OS (median 63 vs 52 months; HR 0.79, 95% CI 0.46–1.35, p=0.39).
Conclusions:
In this real-world cohort of older patients with NDMM, daratumumab-based frontline therapy (Dara-RVd or Dara-Rd) was associated with longer TTNT/death, OS, and fewer acute-care visits than RVd, while Dara-RVd and Dara-Rd showed similar outcomes. In the frail subgroup, both daratumumab-based regimens maintained a TTNT/death advantage over RVd, although a statistically significant OS benefit was observed only with Dara-RVd. Despite the limitations of this retrospective study, these findings support the effectiveness of daratumumab-based frontline therapy in older and frail patients who remain underrepresented in prospective clinical trials.
DISCLOSURES
Okan Cetin, MD: No relevant conflicts of interest to declare.